Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CT-P13 vs Remicade in active rheumatoid arthritis (China, Phase III)
CTR20181685Phase 3Completed
- Sponsor
- Celltrion
- Start
- Oct 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of infliximab-dyyb in rheumatoid arthritis (RA), sponsored by Celltrion. Started Oct 2018; status: completed.
02
Drugs
infliximab-dyyb
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on CTR20181685.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20181685.